ArticleJournal of clinical medicine2026
Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change.
Murat Günaltılı, Murad Guliyev, Zeliha Birsin, Emir Çerme, Vali Aliyev, Hamza Abbasov, Selin Cebeci, Seda Jeral, Ebru Çiçek, Süheyla Atak and 4 more
Abstract read
In one paragraphArticle in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Murat GünaltılıDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0001-6116-3936 Murad GuliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-2981-8098 Zeliha BirsinDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-2645-0785 Emir ÇermeDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Vali AliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Hamza AbbasovDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0003-1227-9996 Selin CebeciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-1758-2321 Seda JeralDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-6594-1712 Ebru ÇiçekDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Süheyla AtakDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Halil Cumhur YıldırımDepartment of Radiation Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Nebi Serkan DemirciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Fazilet Öner DinçbaşDepartment of Radiation Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-4764-9419 Özkan AlanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.ORCID 0000-0002-6635-2012 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
metastasis-directed radiotherapymetastatic hormone-sensitive prostate canceroligoprogressionprostate cancerradiologic progression-free survival
Identifiers
PMID42074868
PMCPMC13116737
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390